Brief: Neuphoria Responds To Lynx1’S Revised Indication Of Interest At A Reduced Price And Premium
04/12/2025 13:17
Dec 4 (Reuters) - Neuphoria Therapeutics Inc NEUP.O: NEUPHORIA RESPONDS TO LYNX1’S REVISED INDICATION OF INTEREST AT A REDUCED PRICE AND PREMIUM NEUPHORIA THERAPEUTICS INC - LYNX1'S NEW BID LOWER THAN INITIAL $4.75 PER SHARE NEUPHORIA THERAPEUTICS INC - RECEIVED SUBSTANTIAL COMPETING INDICATIONS OF INTEREST NEUPHORIA THERAPEUTICS INC - PAUSES RESEARCH AND DEVELOPMENT EXPENDITURES FOR BNC210 IN PTSD & IS EVALUATING ALL POSSIBILITIES AS PART OF THE CO'S STRATEGIC REVIEW NEUPHORIA THERAPEUTICS INC - URGES STOCKHOLDERS TO VOTE "FOR" BOTH OF NEUPHORIA'S NOMINEES ON WHITE PROXY CARD Source text: ID:nGNX5wGcbl Further company coverage: NEUP.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neuphoria Therapeutics
See all newsBrief: Scancell And Neuphoria Therapeutics Announce Merger Agreement And Financing
NASDAQ RESUMED AT 03:25 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 03:20 PM
Brief: Neuphoria Therapeutics Confirms Discussions On Potential Acquisition By Scancell
Brief: Neuphoria Responds To Lynx1’S Revised Indication Of Interest At A Reduced Price And Premium